E-LIB Suche - Ergebnisse für: Budha, Nageshwar

1

Considerations for Industry—Preparing for the FDA Model‐Inf..:

Galluppi, Gerald R. ; Ahamadi, Malidi ; Bhattacharya, Souvik...
Clinical Pharmacology & Therapeutics. , 2024

Link: https://doi.org/10.1002/..

2

Dose Optimization in Oncology Drug Development: An Internat..:

Samineni, Divya ; Venkatakrishnan, Karthik ; Othman, Ahmed A....
Clinical Pharmacology & Therapeutics. , 2024

Link: https://doi.org/10.1002/..

3

Clinical dose rationale of tislelizumab in patients with so..:

Yu, Tian ; Liu, Xiangyu ; Wu, Chi‐Yuan...
Clinical and Translational Science. 17 (2024) 3 - p. , 2024

Link: https://doi.org/10.1111/..

4

A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone a..:

Desai, Jayesh ; Fong, Peter ; Moreno, Victor...
British Journal of Cancer. 128 (2023) 8 - p. 1418-1428 , 2023

Link: https://doi.org/10.1038/..

5

AdvanTIG-105: a phase I dose escalation study of the anti-T..:

Frentzas, Sophia ; Kao, Steven ; Gao, Rang...
Journal for ImmunoTherapy of Cancer. 11 (2023) 10 - p. e005829 , 2023

Link: https://doi.org/10.1136/..

6

Model‐based population pharmacokinetic analysis of tisleliz..:

Budha, Nageshwar ; Wu, Chi‐Yuan ; Tang, Zhiyu...
CPT: Pharmacometrics & Systems Pharmacology. 12 (2022) 1 - p. 95-109 , 2022

Link: https://doi.org/10.1002/..

7

Targeting TIGIT for Immunotherapy of Cancer: Update on Clin..:

Rotte, Anand ; Sahasranaman, Srikumar ; Budha, Nageshwar
Biomedicines. 9 (2021) 9 - p. 1277 , 2021

Link: https://doi.org/10.3390/..

8

Single- and multiple-dose pharmacokinetics, potential for C..:

Malhi, Vikram ; Budha, Nageshwar ; Sane, Rucha...
Cancer Chemotherapy and Pharmacology. 88 (2021) 6 - p. 921-930 , 2021

Link: https://doi.org/10.1007/..

9

Population repeated time‐to‐event analysis of exacerbations..:

Svensson, Robin J ; Ribbing, Jakob ; Kotani, Naoki...
CPT: Pharmacometrics & Systems Pharmacology. 10 (2021) 10 - p. 1221-1235 , 2021

Link: https://doi.org/10.1002/..

10

Exposure–Response‐Based Product Profile–Driven Clinical Uti..:

Zhu, Rui ; Poland, Bill ; Wada, Russ...
CPT: Pharmacometrics & Systems Pharmacology. 8 (2019) 4 - p. 240-248 , 2019

Link: https://doi.org/10.1002/..

11

A PK/PD Analysis of Circulating Biomarkers and Their Relati..:

Netterberg, Ida ; Li, Chi‐Chung ; Molinero, Luciana...
Clinical Pharmacology & Therapeutics. 105 (2018) 2 - p. 486-495 , 2018

Link: https://doi.org/10.1002/..

12

Corrigendum to 'Effects of RG7652, a Monoclonal Antibody Ag..:

Baruch, Amos ; Mosesova, Sofia ; Davis, John D....
The American Journal of Cardiology. 122 (2018) 3 - p. 527 , 2018

Link: https://doi.org/10.1016/..

13

Effects of RG7652, a Monoclonal Antibody Against PCSK9, on ..:

Baruch, Amos ; Mosesova, Sofia ; Davis, John D....
The American Journal of Cardiology. 119 (2017) 10 - p. 1576-1583 , 2017

Link: https://doi.org/10.1016/..

14

Combining "Bottom‐up" and "Top‐down" Approaches to Assess t..:

Lu, Tong ; Fraczkiewicz, Grazyna ; Salphati, Laurent...
CPT: Pharmacometrics & Systems Pharmacology. 6 (2017) 11 - p. 747-755 , 2017

Link: https://doi.org/10.1002/..

15

Methods and strategies for assessing uncontrolled drug–drug..:

Bonate, Peter L. ; Ahamadi, Malidi ; Budha, Nageshwar...
Journal of Pharmacokinetics and Pharmacodynamics. 43 (2016) 2 - p. 123-135 , 2016

Link: https://doi.org/10.1007/..